Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study

Hyperlipidemia is still the leading cause of heart disease in patients with hypertension. The purpose of this study is to make rosuvastatin calcium (ROS) and atenolol (AT) bilayer tablets to treat coexisting dyslipidemia and hypertension with a single product. ROS was chosen for the immediate-releas...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsayed, Mahmoud M. A., Aboelez, Moustafa O., Mohamed, Mohamed S., Mahmoud, Reda A., El-Shenawy, Ahmed A., Mahmoud, Essam A., Al-Karmalawy, Ahmed A., Santali, Eman Y., Alshehri, Sameer, Elsadek, Mahmoud Elkot Mostafa, El Hamd, Mohamed A., Ramadan, Abd El hakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412892/
https://www.ncbi.nlm.nih.gov/pubmed/36015255
http://dx.doi.org/10.3390/pharmaceutics14081629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412892/
https://www.ncbi.nlm.nih.gov/pubmed/36015255
http://dx.doi.org/10.3390/pharmaceutics14081629

Ejemplares similares